Globally, around 700 million people live with chronic kidney disease (CKD), with many more likely still undiagnosed. These patients frequently have fluctuating blood potassium levels, which exposes them to possible cardiac complications. The associated cardiovascular events account for up to 30% of deaths in patients with chronic kidney disease.
Attempting to tackle the problem, Grenoble-based company CardioRenal has raised €3.3 million from angels and longstanding company shareholders to offer treatment at home for patients with severe CKD. Its platform enables doctors to optimise patient treatment through remote monitoring of key blood biomarkers.
The seed funding will enable the startup to complete the process of obtaining regulatory approval for its connected medical device, which it plans to roll out in 2023. The company completed a clinical trial on the technology in October 2021. The results of this trial will be presented at the European Renal Association congress in Paris in May.
Maurice Bérenger, CEO, CardioRenal said: “This fundraising will support our roadmap for our forthcoming launch in Europe and the U.S.”